Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 25, 2010, Pages 11501-11506

  Wiedemeyer, W Ruprecht ^a,b   Dunn, Ian F ^a,c,d,e   Quayle, Steven N ^a,b   Zhang, Jianhua ^b   Chheda, Milan G ^a,c,d   Dunn, Gavin P ^a,c,d   Zhuang, Li ^a,b   Rosenbluh, Joseph ^a,c,d   Chen, Shujuan ^a,b   Xiao, Yonghong ^b   Shapiro, Geoffrey I ^a,e   Hahn, William C ^a,c,d,e   Chin, Lynda ^a,b,c,d,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Belfer Institute for Innovative Cancer Science   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cyclin dependent kinase inhibitor; INK4C; PD0332991; Targeted therapy

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 (5 PIPERAZIN 1 YLPYRIDIN 2 YLAMINO) 8H PYRIDO(2,3 D)PYRIMIDIN 7 ONE; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-(5-PIPERAZIN-1-YLPYRIDIN-2-YLAMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CDKN2C PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2C; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE DELETION; GENETIC ANALYSIS; GENETIC SCREENING; GLIOBLASTOMA; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RETINOBLASTOMA; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; DOSE RESPONSE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; IC 50; METABOLISM; MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NEOPLASM TRANSPLANTATION; PIPERAZINES; PYRIDINES; RETINOBLASTOMA PROTEIN;

EID: 77954929373     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1001613107     Document Type: Article

References (21)

1. Bild AH, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357.
2. Atlas CG; Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
3. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 9:153-166.
4. Stupp R, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996.
5. Moffat J, et al. (2006) A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124:1283-1298.
6. Wiedemeyer R, et al. (2008) Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell 13:355-364.
7. Solomon DA, et al. (2008) Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme. Cancer Res 68:2564-2569.
8. Bachoo RM, et al. (2002) Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269-277.
9. He J, et al. (1994) CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54:5804-5807.
10. Fry DW, et al. (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427-1438.
11. Costello JF, et al. (1997) Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 57: 1250-1254.
12. Malumbres M, Pevarello P, Barbacid M, Bischoff JR (2008) CDK inhibitors in cancer therapy: What is next? Trends Pharmacol Sci 29:16-21.
13. Santamaría D, et al. (2007) Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448:811-815.
14. Michaud K, et al. (2010) Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 70: 3228-3238.
15. Finn RS, et al. (2009) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11:R77.
16. Eguchi T, et al. (2009) Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines. Mol Cancer Ther 8:1460-1472.
17. Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2: 103-112.
18. Boehm JS, et al. (2007) Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129:1065-1079.
19. Scholl C, et al. (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821-834.
20. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R (2006) Statistical practice in high-throughput screening data analysis. Nat Biotechnol 24:167-175.
21. Beroukhim R, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci USA 104: 20007-20012.